Free Trial
OTCMKTS:CVSI

CV Sciences (CVSI) Stock Price, News & Analysis

CV Sciences logo
$0.03 0.00 (-6.33%)
As of 06/23/2025 03:59 PM Eastern

About CV Sciences Stock (OTCMKTS:CVSI)

Key Stats

Today's Range
$0.03
$0.04
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.06
Volume
1.01 million shs
Average Volume
168,399 shs
Market Capitalization
$5.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

CV Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

CVSI MarketRank™: 

CV Sciences scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for CV Sciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CV Sciences is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CV Sciences is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CV Sciences has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.01% of the float of CV Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    CV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CV Sciences has recently decreased by 80.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CV Sciences does not currently pay a dividend.

  • Dividend Growth

    CV Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of CV Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    CV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CV Sciences has recently decreased by 80.26%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for CV Sciences this week, compared to 0 articles on an average week.
Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Stock News Headlines

Q1 2025 CV Sciences Inc Earnings Call
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Q4 2024 CV Sciences Inc Earnings Call
See More Headlines

CVSI Stock Analysis - Frequently Asked Questions

CV Sciences' stock was trading at $0.0338 at the start of the year. Since then, CVSI shares have decreased by 16.9% and is now trading at $0.0281.
View the best growth stocks for 2025 here
.

CV Sciences, Inc. (OTCMKTS:CVSI) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $5.13 million for the quarter, compared to the consensus estimate of $5.12 million. CV Sciences had a negative net margin of 12.25% and a negative trailing twelve-month return on equity of 89.43%.

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), Kushco (KSHB), NVIDIA (NVDA) and Organigram Global (OGI).

Company Calendar

Last Earnings
8/12/2021
Today
6/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.39 million
Pretax Margin
-12.29%

Debt

Sales & Book Value

Annual Sales
$15.70 million
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
2.81

Miscellaneous

Free Float
182,392,000
Market Cap
$5.19 million
Optionable
Not Optionable
Beta
0.47

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:CVSI) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners